COVID-19 (Coronavirus Disease 2019)
Also known as: COVID-19, Coronavirus
Methodology & AI Transparency ⓘ
COVID-19 (Coronavirus Disease 2019) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: COVID-19 (coronavirus disease 2019) is an illness caused by a virus.
- 2 Real-world patient consensus: Synonyms for COVID-19 (Coronavirus Disease 2019) (J06.6): COVID-19, Coronavirus (Infections & Antivirals).
- 3 Typical cash cost range: Differential triage of COVID-19 (Coronavirus Disease 2019) (J06.6) utilizes antimicrobial stewardship (narrow-spectrum in COVID-19 (Coronavirus Disease 2019) (J06.6: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for COVID-19 (Coronavirus Disease 2019) (J06.6): Targeted PCR / in COVID-19 (Coronavirus Disease 2019) (J06.6: Culture & Sensitivity) & Complete Blood Count in COVID-19 (Coronavirus Disease 2019) (J06.6: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (J06.6)).
Ask our AI Specialists anything about COVID-19 (Coronavirus Disease 2019)
What Is COVID-19 (Coronavirus Disease 2019)?
COVID-19 (coronavirus disease 2019) is an illness caused by a virus. This virus is a coronavirus called SARS-CoV-2. It spreads when a person who has the infection breathes out droplets and very small particles that contain the virus. On this page, you'll find links to resources on important issues such as symptoms, risks, and how you can protect yourself and your family. We also have pages on: COVID-19 testing COVID-19 vaccines Post-COVID conditions (long COVID)
Pathophysiology, Underlying Causes & Clinical Presentation
COVID-19 (Coronavirus Disease 2019) (J06.6) alters infections & antivirals homeostasis through microbial (bacterial [COVID-19 (Coronavirus Disease 2019) J06.6]; Cross-referenced with NIH MeSH (COVID-19), clinical remission targets Complete Blood Count in COVID-19 (Coronavirus Disease 2019) (J06.6: (WBC & Differential)) within WBC 4.0 – 10.0 x10^3/uL (J06.6).
Common Symptoms & Clinical Signs
- • Post-COVID conditions (long COVID)
- • Presentation of COVID-19 (Coronavirus Disease 2019) (J06.6): acute fever, chills, in COVID-19 (Coronavirus Disease 2019) (J06.6: malaise, and myalgias)
- • Secondary COVID-19 (Coronavirus Disease 2019) clinical sign: sore throat, productive in COVID-19 (Coronavirus Disease 2019) (J06.6: cough, sinus/ear pain,)
- • Symptom flares in COVID-19 (Coronavirus Disease 2019) correlating with Targeted PCR / in COVID-19 (Coronavirus Disease 2019) (J06.6: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (J06.6)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
COVID-19 (Coronavirus Disease 2019) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J06.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in COVID-19 (Coronavirus Disease 2019) (J06.6: Culture & Sensitivity) | Pathogen clearance / negative test (J06.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in COVID-19 (Coronavirus Disease 2019) (J06.6: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (J06.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in COVID-19 (Coronavirus Disease 2019) (J06.6: Procalcitonin) | Resolution to baseline (J06.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for COVID-19 (Coronavirus Disease 2019)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nirmatrelvir and Ritonavir Paxlovid • RxCUI 900575 | FDA Prescription Therapeutic Agent | 77% | $49.2332 | $ 185.00 /mo |
| Remdesivir Veklury • RxCUI 2284960 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor | 90% | $2.2500 | $ 99.63 /mo |
| Veklury (Remdesivir) Veklury • RxCUI 2367758 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor | 92% | $1.0900 | $ 86.98 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (COVID-19 (Coronavirus Disease 2019))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with: What a 1,212-Participant Study Found Olgotrelvir as a single-agent treatment significantly improved symptom recovery. NEJM evidence • 2024-06-15 • Phase III Randomized Trial | N = 1,212 | 96/100 | PMID 38804790 ↗ |
| New Insights on Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response: What a 1,313-Participant Study Found The E-R results support the MOV dose of 800 mg twice daily to treat COVID-19. Clinical pharmacology and therapeutics • 2023-06-15 • Phase III Randomized Trial | N = 1,313 | 96/100 | PMID 37017631 ↗ |
| New Insights on Molnupiravir for the treatment of COVID-19 in immunocompromised participants:: What a 1,408-Participant Study Found Although the study population was small, these data suggest that molnupiravir treatment for mild-to-moderate COVID-19 in non-hospitalized immunocompromised adults is efficacious and safe and quickly reduces infectious SARS-CoV-2. Infection • 2023-10-15 • Phase III Randomized Trial | N = 1,408 | 96/100 | PMID 36648627 ↗ |
| New Insights on Prevention of post COVID-19 condition by early treatment with ensitrelvir in the: What a 333-Participant Study Found Ensitrelvir treatment in the acute phase of COVID-19 may reduce the risk of various symptoms associated with PCC. Antiviral research • 2024-09-15 • Phase III Randomized Trial | N = 333 | 93/100 | PMID 38972603 ↗ |
| New Insights on Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized: What a 302-Participant Study Found CONCLUSIONS: These interim study results support further evaluation of molnupiravir as a potential treatment to reduce hospitalizations and/or death in nonhospitalized patients with Covid-19. NEJM evidence • 2022-02-15 • Phase III Randomized Trial | N = 302 | 93/100 | PMID 38319179 ↗ |
COVID-19 (Coronavirus Disease 2019) Patient Community & “People Like Me” Threads
Filter COVID-19 (Coronavirus Disease 2019) community threads and patient logs by age, biological sex, dosage, and treatment duration.